A substantial loss of muscle mass and strength (sarcopenia), a decreased regenerative
capacity, and a compromised physical performance are hallmarks of aging skeletal muscle …

Inhibitors of myostatin, a negative regulator of skeletal muscle mass, are being developed to
mitigate aging‐related muscle loss. Knock‐out (KO) mouse studies suggest myostatin also …

Breast cancer represents the most commonly diagnosed cancer while neoadjuvant and
adjuvant chemotherapies are extensively used in order to reduce tumor development and …

Myotonic dystrophy type 1 (DM1 or Steinert's disease) and type 2 (DM2) are multisystem
disorders of genetic origin. Progressive muscular weakness, atrophy and myotonia are the …

Background: Sarcopenia, the age-related loss of muscle mass and function, represents a
relevant public health issue due to its high prevalence and detrimental consequences. While …

Physical inactivity has recently been identified as a major and independent risk factor for the
development of dementia and cognitive decline. In addition to the effect of exercise with …

Sarcopenia and osteoporosis have recently been noted for their relationship with locomotive
syndrome and increased number of older people. Sarcopenia is defined by decreased …

Myostatin is a negative regulator of skeletal muscle growth and in fact acts as a potent
inducer of “cachectic-like” muscle wasting in mice. The mechanism of action of myostatin in …

Aging is inevitably associated with a progressive loss of muscle mass and strength, a
condition also known as sarcopenia of aging. Although the precise mechanisms underlying …

Muscle loss during aging and disuse is a highly prevalent and disabling condition, but
knowledge about cellular pathways mediating muscle atrophy is still limited. Given the …